On March 31, 2026, Medicilon officially signed a long-term strategic cooperation framework agreement with BioPartners X. Mr. Gong Huimin, Chairman and CEO of BioPartners X, Dr. Liu Tong, Chief Scientist, Mr. Luo Wusong and Mr. Xu Changlu, Vice Presidents of Strategic Investment, and Mr. Li Ao, Non-Clinical Director, together with Dr. Chen Chunlin, Founder and CEO of Medicilon, and Ms. Wang Mingying, Senior Director of Business Development, attended the signing ceremony.
At the signing ceremony, both parties held in-depth discussions on the directions of future cooperation. BioPartners X has strong capabilities in the transformation of scientific research achievements from universities. With a development vision of building a pipeline of 100 innovative drug IND candidates, BioPartners X boasts enormous innovation potential and broad development prospects. Medicilon and BioPartners X have agreed to fully share resources in business development, industry channels and industrial information, further expand cooperation scenarios, enhance collaboration efficiency, and jointly build a highly interconnected ecosystem for innovative drug research and development. Within the agreed cooperation period, the two parties will focus on innovative drug R&D for major diseases, with the goal of achieving 5 IND submissions, and jointly set a benchmark for cooperation between CROs and innovative pharmaceutical companies.
Complementary Advantages for Long-Term Cooperation
As a leading one-stop preclinical R&D platform, Medicilon offers a comprehensive service system covering drug discovery, CMC, preclinical research and IND registration and filing. With international GLP certifications and extensive project experience, Medicilon has helped over 2,000 global clients accelerate new drug development.
Hand in Hand to Accelerate Innovative Drug R&D
Chunlin Chen,Chairman and CEO of Medicilon
Medicilon will fully serve as a solid backing for BioPartners X in its innovative drug R&D journey and provide all-round support as it advances toward developing 100 innovative drugs. Leveraging its advantages in one-stop full-process R&D services, Medicilon will coordinate high-quality resources, deeply align with BioPartners X’s R&D needs, and efficiently promote the implementation and effectiveness of cooperative projects.
Huimin Gong,Chairman and CEO of BioPartners X
Medicilon’s technological strength, project experience and service quality in new drug R&D will provide strong support for BioPartners X’s innovative drug pipeline layout and help steadily achieve its long-term strategic goals.
